BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025

Core Viewpoint - BioStem Technologies, Inc. is progressing towards a Nasdaq uplisting by filing its audited consolidated financial statements for the fiscal years ended December 31, 2024, and 2025, marking a significant milestone for the company [1][2]. Financial Progress - The company has published its audited financial statements for 2024 and 2025, which is a crucial step in establishing robust financial reporting processes [2]. - The appointment of a new CFO, auditor, and audit committee chair further emphasizes the company's commitment to improving its financial governance [2]. Corporate Strategy - Listing on Nasdaq is a top priority for BioStem, as it would enhance visibility, improve stock liquidity, provide a more accurate market valuation, and attract top talent [2]. - The company is focused on advancing its corporate initiatives, including the development and commercialization of perinatal tissue allograft products [1][2]. Quality Assurance - BioStem's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks (AATB), ensuring compliance with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [3]. - The company offers a portfolio of quality brands, including Neox, Clarix, VENDAJE, and American Amnion™ [3]. Company Overview - BioStem Technologies is a publicly traded biomedical innovator specializing in advanced allograft solutions derived from perinatal tissue, utilizing proprietary technologies like BioRetain, CryoTek, and SteriTek [2]. - The company is committed to advancing innovation in regenerative medicine with a growing portfolio of products and expanding clinical research initiatives [2].